This is a randomized, multicenter trial with stratification done by a single radiologist at
the coordinating center (NYU), and patients with comparable disease will be randomized to
Sandostatin LAR treatment administered 1 time per month by IM injection for 3 months before
(Arm A) or, for non-cured patients, after (Arm B) surgery. All patients will undergo
transsphenoidal hypophysectomy. The impact of surgical debulking on responsiveness to
Sandostatin LAR will be evaluated.The primary objective of this trial will be to determine
whether surgery (debulking of pituitary adenomas) improves the response of patients with
acromegaly to treatment with Octreotide LAR, when compared to Octreotide LAR therapy alone.
Phase:
Phase 4
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health